一年一度的美国临床肿瘤学会（ASCO）年会即将于2026年5月29日至6月2日在美国芝加哥盛大开启！作为肿瘤领域的年度盛会，ASCO将一如既往地带来最前沿的肿瘤研究进展与诊疗理念，备受领域关注！当前，ASCO官网发布了2026 ASCO年会的摘要标题，【肿瘤资讯】特此整理白血病领域的重磅研究，带大家先睹为快！
Oral Abstract Session
口头报告专场
摘要号：6503
第一作者（以下简称：一作）：Jennifer Marvin-Peek | The University of Texas MD Anderson Cancer Center
英文标题：A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML)
中文标题：阿扎胞苷、维奈克拉联合艾伏尼布治疗IDH1突变急性髓系白血病（AML）的多中心Ⅰb/Ⅱ期临床试验
摘要号：6504
一作：Musa Yilmaz | The University of Texas MD Anderson Cancer Center
英文标题：Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory FLT3-mutated AML
中文标题：奎扎替尼联合地西他滨与维奈克拉治疗初治及复发/难治性FLT3突变AML
摘要号：6505
一作：Hannah Goulart | The University of Texas MD Anderson Cancer Center
英文标题：Revumenib as maintenance for AML following allogeneic stem cell transplantation
中文标题：Revumenib用于异基因造血干细胞移植后AML的维持治疗
摘要号：6506
一作：王华锋 | 浙江大学医学院附属第一医院
英文标题：Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies
中文标题：Mesutoclax（ICP-248）联合阿扎胞苷治疗髓系恶性肿瘤患者的安全性、耐受性与有效性
摘要号：6507
一作：Mendel Goldfinger | Montefiore Medical Center
英文标题：Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML)
中文标题：Eganelisib治疗高危骨髓增生异常综合征（HR-MDS）或复发/难治性（R/R）AML成人患者的安全性与有效性
摘要号：6508
一作：吕萌 | 北京大学人民医院
英文标题：First-in-human dual-epitope nanobody anti-CD5 CAR-T for relapsed/refractory T-ALL/PTCL: Phase I dose-escalation and expansion results from the CONQUER trial
中文标题：双表位纳米抗体CD5 CAR-T细胞治疗复发/难治性T-ALL/PTCL的首次人体试验：CONQUER试验Ⅰ期剂量递增及扩展研究结果
Rapid Oral Abstract Session
快速口头报告
摘要号：6509
一作：Andrew Kuykendall | H. Lee Moffitt Cancer Center and Research Institute
英文标题：A phase 2 study of fedratinib in patients with MDS/MPN and chronic neutrophilic leukemia
中文标题：Fedratinib治疗骨髓增生异常综合征/骨髓增殖性肿瘤（MDS/MPN）及慢性中性粒细胞白血病患者的Ⅱ期研究
摘要号：6510
一作：黎纬明 | 华中科技大学同济医学院附属协和医院
英文标题：Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
中文标题：奥雷巴替尼（HQP1351）作为慢性髓系白血病慢性期（CP-CML）二线治疗的最新疗效与安全性数据
摘要号：6511
一作：Manju Sengar | Tata Memorial Hospital
英文标题：A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML)
中文标题：传统3+7方案对比阿扎胞苷 + 维奈克拉（AZA+VEN）用于AML诱导治疗的疗效、时间毒性及成本的前瞻性观察研究
摘要号：6512
一作：Timothy Pardee | Comprehensive Cancer Center of Atrium Health Wake Forest Baptist
英文标题：A randomized phase Ⅱ study of selinexor added to standard induction and consolidation chemotherapy in adults with acute myeloid leukemia (AML)
中文标题：标准诱导及巩固化疗联合塞利尼索治疗成人AML的随机Ⅱ期研究
摘要号：6513
一作：Elias Jabbour | The University of Texas MD Anderson Cancer Center
英文标题：Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
中文标题：奥雷巴替尼（HQP1351）联合贝林妥欧单抗治疗慢性髓系白血病淋系急变期（CML-LBP）或费城染色体阳性B细胞前体急性淋巴细胞白血病（Ph+ BCP-ALL）患者
摘要号：6514
一作：Lewis Nasr | The University of Texas MD Anderson Cancer Center
英文标题：Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia
中文标题：贝林妥欧单抗联合泊那替尼无化疗方案治疗新诊断费城染色体阳性B细胞急性淋巴细胞白血病（B-ALL）的更新结果
摘要号：6515
一作：Lewis Nasr | The University of Texas MD Anderson Cancer Center
英文标题：Long-term outcomes with addition of inotuzumab ozogamicin to HCVAD and sequential blinatumomab in adults with newly diagnosed B-ALL
中文标题：HCVAD方案联合奥加伊妥珠单抗序贯贝林妥欧单抗治疗初治成人B-ALL的长期治疗结局
摘要号：6516
一作：Maria Hachem | The University of Texas MD Anderson Cancer Center
英文标题：The impact of MRD and post-remission strategies on outcomes following dose-dense mini-hyper-CVD inotuzumab and blinatumomab in relapsed B-cell acute lymphoblastic leukemia.
中文标题：MRD及缓解后策略对剂量密集型mini-hyper-CVD方案联合奥加伊妥珠单抗与贝林妥欧单抗治疗复发B细胞急性淋巴细胞白血病的预后影响
摘要号：6517
一作：Jae Park | Memorial Sloan Kettering Cancer Center
英文标题：The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease(EMD)
中文标题：Obe-cel治疗成人复发/难治性B细胞急性淋巴细胞白血病（R/R B-ALL）和髓外病变（EMD）患者的疗效
*ASCO官方摘要将持续更新，本文信息仅供参考，最新内容请以 ASCO 官网发布为准，如有疏漏，欢迎补充指正。
排版编辑：Mathilda
苏公网安备32059002004080号
